Sign In
Buy EXEL
$51.60
+3.06 (+6.30%)
At Close: Jun 03, 2026
3 Stocks With Upgraded Broker Ratings to Consider for Solid Returns
09:51am, Friday, 27'th Jun 2025
EXEL, LYFT and KGC have all seen notable broker upgrades recently. Here???s why they may offer solid returns ahead.
3 Reasons Growth Investors Will Love Exelixis (EXEL)
01:46pm, Wednesday, 25'th Jun 2025
Exelixis (EXEL) could produce exceptional returns because of its solid growth attributes.
Exelixis (EXEL) Surges 7.4%: Is This an Indication of Further Gains?
11:46am, Tuesday, 24'th Jun 2025
Exelixis (EXEL) witnessed a jump in share price last session on above-average trading volume. The latest trend in earnings estimate revisions for the stock suggests that there could be more strength d
Here's Why Exelixis (EXEL) is a Strong Momentum Stock
10:56am, Tuesday, 24'th Jun 2025
The Zacks Style Scores offers investors a way to easily find top-rated stocks based on their investing style. Here's why you should take advantage.
EXEL Stock Rises on Positive Data From Colorectal Cancer Study
10:41am, Tuesday, 24'th Jun 2025
EXEL jumps 7.4% as STELLAR-303 trial hits key survival goal in colorectal cancer, boosting hopes for an approval of zanzalintinib.
Exelixis, Inc. (EXEL) Soars to 52-Week High, Time to Cash Out?
10:15am, Tuesday, 24'th Jun 2025
Exelixis (EXEL) is at a 52-week high, but can investors hope for more gains in the future? We take a look at the company's fundamentals for clues.
Buy 5 High-Flying Non-Tech Nasdaq-Listed Stocks of H1 to Gain in H2
08:31am, Tuesday, 24'th Jun 2025
Nasdaq is flat in first-half 2025, but SFM, RGLD, TRI, WWD and EXEL are soaring, each up over 20% and primed for the second half.
Exelixis: Zanzalintinib MOA Overcomes Competing CRC Regorafenib Treatment
12:58pm, Monday, 23'rd Jun 2025
Exelixis is a strong buy due to robust CABOMETYX sales growth, with Q1 2025 revenues up 36% year-over-year and raised full-year 2025 guidance. Positive phase 3 STELLAR-303 results for zanzalintinib pl
Exelixis' Zanzalintinib Combo Boosts Survival In Colorectal Cancer, Stock Soars
10:37am, Monday, 23'rd Jun 2025
On Sunday, Exelixis, Inc. EXEL revealed topline results from the STELLAR-303 phase 3 pivotal trial of zanzalintinib (100 mg) combined with atezolizumab.
ALAMEDA, Calif.--(BUSINESS WIRE)--Exelixis, Inc. (Nasdaq: EXEL) today announced positive topline results from the STELLAR-303 phase 3 pivotal trial in which zanzalintinib in combination with atezolizu
ALAMEDA, Calif.--(BUSINESS WIRE)--Exelixis, Inc. (Nasdaq: EXEL) today announced that its partner Ipsen received a positive opinion from the European Medicine Agency's (EMA) Committee for Medicinal Pro
Here's Why Exelixis (EXEL) is a Strong Value Stock
10:45am, Wednesday, 18'th Jun 2025
Whether you're a value, growth, or momentum investor, finding strong stocks becomes easier with the Zacks Style Scores, a top feature of the Zacks Premium research service.
EXEL or ARGX: Which Is the Better Value Stock Right Now?
12:41pm, Tuesday, 17'th Jun 2025
Investors interested in stocks from the Medical - Biomedical and Genetics sector have probably already heard of Exelixis (EXEL) and argenex SE (ARGX). But which of these two companies is the best opti
4 Attractive GARP Picks for Your Portfolio Based on PEG Ratio
04:01pm, Thursday, 12'th Jun 2025
Here are four discounted PEG stocks that qualify our screening criteria and could be good picks. These are FLEX, CVS, URBN and EXEL.
Why Is Exelixis (EXEL) Down 7.2% Since Last Earnings Report?
12:30pm, Thursday, 12'th Jun 2025
Exelixis (EXEL) reported earnings 30 days ago. What's next for the stock?
